The Economist, one of the more worthy media sources these days for connecting technology to larger society, included a page on nanomedicine in its special issue, “The World in 2013.” (page 128). The article is by Professors Omid Farokhzad and Rober Langer and focuses on bio nanotechnology from BIND Biosciences. BIND recently announced a development deal with Amgen. Professor Langer is a founder of BIND and Professor Farokhzad also works closely with BIND (according to the BIND Web page). The technology is for polymeric nanoparticles which smartly carry a payload. Cancer treatment is a leading application. Patenting is an important part of the company strategy per their press releases and web page content.
The attached link has information for an upcoming nanomedicine conference in April in Spain.
Lets hope more deals are in the works for nanomedicine as 2013 moves ahead into the market place from academic research. Venture capital is an important part of this story.